Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.
Thomas Newcomer
Advertisement
Thomas Newcomer is senior vice president and head of US commercial
Samsung Bioepis.
Articles by Thomas Newcomer
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Aradhana Sarin: The CFO as a Catalyst
2
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
3
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
4
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
5